A crucial insight gained from a recent successful therapeutic AD trial indicated that individuals with ‘low/medium’ brain tau levels derived greater benefit from Aβ monoclonal antibody treatment compared to those with a ‘high’ brain tau burden defined as the upper quartile of Aβ+ MCI/AD individuals on tau PET.1 This evidence concerns the gene MAPT and Alzheimer disease.